Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for BlackThorn Therapeutics

    Client Virtual Booth

    BLACKTHORN THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    BlackThorn Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    780 Brannan Street San Francisco, CA 94103
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.blackthornrx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/blackthorn-therapeutics
    Twitter
    Twitter
    https://twitter.com/BlackThornRX

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist
    BlackThorn Advances Phase 2 Clinical Development for Selective KOR Antagonist

    https://www.biospace.com/article/releases/blackthorn-therapeutics-advances-phase-2-clinical-development-for-selective-kor-antagonist-btrx-140-in-neuropsychiatric-disorders/

    BIO SPACE
    23 Jan 2020
    Share Share
    Polaris Partners — maps $400M for ninth fund
    Polaris Partners — maps $400M for ninth fund

    https://endpts.com/bob-langers-first-port-of-call-polaris-partners-maps-400m-for-ninth-fund/

    Natalie Grover ENDPTS
    20 Jun 2019
    Share Share
    BlackThorn bags $76M to push targeted treatments for brain disorders
    BlackThorn bags $76M to push targeted treatments for brain disorders

    https://www.fiercebiotech.com/biotech/blackthorn-bags-76m-to-push-targeted-treatments-for-brain-disorders

    Amirah Al Idrus FIERCE BIOTECH
    13 Jun 2019
    Share Share
    BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140
    BlackThorn Announces Positive Ph 1 Results KOR Antagonist, BTRX-335140

    https://www.businesswire.com/news/home/20190401005191/en/BlackThorn-Therapeutics-Announces-Positive-Phase-1-Results/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==

    BUSINESSWIRE
    01 Apr 2019
    Share Share
    BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer
    BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer

    https://www.businesswire.com/news/home/20181105005261/en/BlackThorn-Therapeutics-Names-Bill-Martin-Ph.D.-President

    BUSINESSWIRE
    08 Nov 2018
    Share Share
    Biomatics raises $300M for healthcare fund, recruits biopharma veterans
    Biomatics raises $300M for healthcare fund, recruits biopharma veterans

    https://www.fiercebiotech.com/biotech/biomatics-raises-300m-healthcare-fund-recruits-biopharma-vets

    Amirah Al Idrus FIERCE BIOTECH
    08 Nov 2018
    Share Share
    Jnana President Joanne Kotz to take on CEO role
    Jnana President Joanne Kotz to take on CEO role

    https://www.fiercebiotech.com/biotech/jnana-president-joanne-kotz-to-take-ceo-role

    Conor Hale FIERCE BIOTECH
    07 Nov 2018
    Share Share
    BlackThorn Announces Exclusive Licensing Agreement & Yale University
    BlackThorn Announces Exclusive Licensing Agreement & Yale University

    http://www.blackthornrx.com/blackthorn-therapeutics-announces-exclusive-licensing-agreement-and-extension-of-key-collaboration-with-yale-university/

    PRESS RELEASE
    06 Aug 2018
    Share Share
    BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors
    BlackThorn Therapeutics Names George S. Golumbeski, Ph.D., to Board of Directors

    http://www.blackthornrx.com/blackthorn-therapeutics-names-george-s-golumbeski-ph-d-to-board-of-directors/

    PRESS RELEASE
    12 Jun 2018
    Share Share
    BlackThorn Initiates Ph1 Study of BTRX-335140, Investigational (KOR) Antagonist
    BlackThorn Initiates Ph1 Study of BTRX-335140, Investigational (KOR) Antagonist

    http://www.blackthornrx.com/blackthorn-therapeutics-initiates-phase-1-study-of-btrx-335140-an-investigational-kappa-opioid-receptor-kor-antagonist/

    PRESS RELEASE
    06 Jun 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search